Our primary research and efforts will focus on breast, lung cancer, and female gynaecological cancers, while also maintaining a business line dedicated to reformulating off-patent generic drugs for selected pharma and biotech clients. Prosemble has been forming strategic partnerships with clinicians, hospitals, and pharmaceutical companies, ensuring rapid development, clinical testing, and commercialisation of the technology. 

HER2 is frequently overexpressed in breast cancer, making it a valuable target for therapy. To exploit this, a targeting peptide (LTVSPWY) is employed to guide nanoparticles specifically to HER2-positive tumour cells. These nanoparticles are designed to assemble in the presence of ATP and disassemble through hydrolysis, enabling controlled drug release. Two types of nanoparticles, PNPT and PNPN, were successfully characterised by cryo-electron microscopy and demonstrated effective loading of Doxorubicin. Their therapeutic efficacy will be evaluated in mice by measuring tumour burden, survival rates, and comparing drug performance. Furthermore, toxicity and immune responses will be assessed by examining lymph node histology and antibody levels.

Approximately 35% of lung cancers, particularly in non-smokers, exhibit overexpression of the epidermal growth factor receptor (EGFR), making it a key target for personalised therapy. Prosemble’s technology enables the precise delivery of anticancer drug cocktails to EGFR-positive tumour cells, enhancing efficacy while minimising off-target toxicity. These nanoparticles not only transport drugs directly to cancer cells but also inhibit EGFR activity, thereby reducing tumour cell proliferation and contributing to more effective treatment.

There are five main gynaecological cancers, with ovarian cancer—characterised by overexpression of the NR3C4 receptor—prioritised first for targeted nanoparticle drug delivery. Folate Receptor Alpha, EGFR, and CD44 are also considered promising future targets in cervical and ovarian cancers due to their roles in tumour growth, drug resistance, and metastasis. Mesothelin and integrins (e.g., αvβ3) offer additional tumour-specific targeting opportunities, as their expression is limited in normal tissues, supporting more precise nanoparticle delivery. Moreover, BRCA1 and BRCA2 gene mutations, commonly found in both breast and ovarian cancers, establish a genetic link between the diseases and present opportunities for shared targeted treatment strategies.NR3C4 is increasingly recognised as a contributing factor in the development and progression of ovarian cancer, although its role remains complex and is still under active investigation. While it has also been studied in cervical cancer, its involvement is less well understood compared to its established role in prostate and ovarian cancers. Some research suggests it may influence tumour growth or progression, particularly through HPV-related pathways, but current findings are mixed and warrant further study.

The technology reformulates out-of-patent oncology drugs to create higher-quality, less toxic products offered at a premium price. It enables market entry with differentiated, patentable formulations, positioning the company for competitive advantage. Minimal reformulation costs accelerate development, allowing faster market entry and reduced launch expenses. This approach is particularly well-suited to recent or prospective entrants in the oncology field, including those transitioning from related or adjacent sectors.